Publications by authors named "H Janicot"
Introduction: The prognosis of metastatic non-small cell lung cancer (NSCLC) has been improved by the use of immune checkpoint inhibitors (ICI). Unfortunately, in some cases, cancer cells will develop resistance mechanisms. In case of progression in a limited number of lesions (oligoprogression), focal treatment with radiotherapy is proposed while continuing the ICI therapy.
View Article and Find Full Text PDFTelomere length appears to correlate with survival in early non-small-cell lung cancer (NSCLC), but the prognostic impact of telomere status in advanced NSCLC remains undetermined. Our purpose was to evaluate telomere parameters as prognostic and predictive biomarkers in advanced NSCLC. In 79 biopsies obtained before treatment, we analyzed the telomere length and expression of and shelterin complex genes (, , , , , and ), using quantitative PCR.
View Article and Find Full Text PDFArticle Synopsis
- Targeted therapies (TT) and immune checkpoint blockers (ICB) are changing the treatment landscape for non-small cell lung cancer (NSCLC), but their effectiveness as maintenance therapies after first-line chemotherapy is unclear.
- The SAFIR02-Lung trial involved 175 patients receiving various TT and 59 receiving standard care, showing no significant difference in progression-free survival (PFS) between the two groups.
- The study concluded that while molecular profiling for treatment decisions can be managed, it didn’t show significant advantages for most patients, except those with a specific PD-L1 tumor score who benefited more from durvalumab treatment.
Introduction: HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating tumor DNA (ctDNA) was a prognostic marker in LC patients from the general population. This study assessed ctDNA's prognostic value in PLHIV from a dedicated phase II trial.
View Article and Find Full Text PDFBackground: Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line treatment in patients with sensitive relapsed small-cell lung cancer.
Methods: In this open-label, randomised, phase 3 trial done in 38 hospitals in France, we enrolled patients with histologically or cytologically confirmed advanced stage IV or locally relapsed small-cell lung cancer, who responded to first-line platinum plus etoposide treatment, but who had disease relapse or progression at least 90 days after completion of first-line treatment.